首页|AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
The AML1-ETO fusion transcription factor is generated by the t(8;21) translocation,which is present in approximately 4％-12％ of adult and 12％-30％ of pediatric acute myeloid leukemia (AML) patients.Both human and mouse models of AML have demonstrated that AML1-ETO is insufficient for leukemogenesis in the absence of secondary events.In this review,we discuss the pathogenetic insights that have been gained from identifying the various events that can cooperate with AML1-ETO to induce AML in vivo.We also discuss potential therapeutic strategies for t(8;21) positive AML that involve targeting the fusion protein itself,the proteins that bind to it,or the genes that it regulates.Recently published studies suggest that a targeted therapy for t(8;21) positive AML is feasible and may be coming sometime soon.
AML 1-ETOmouse modelleukemiat(821)pathway hitsmutationhematopoiesisKasumi-1CD34+
Megan A.Hatlen、Lan Wang、Stephen D.Nimer
展开 >
Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
Weill Cornell Medical College, New York, NY 10065, USA
NETL
NSTL
万方数据
